Newsletter
COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

Mayo Clinic Talks

COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

This episode was recorded on June 5, 2020. To claim credit visit: https://ce.mayo.edu/covid19podcast Guest: Raymund R. Razonable, M.D. (@RazonableMD) Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)  Up to about 50%…
June 8, 2020

COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

This episode was recorded on June 5, 2020.

To claim credit visit: https://ce.mayo.edu/covid19podcast

Guest: Raymund R. Razonable, M.D. (@RazonableMD)

Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006

Up to about 50% of people infected with SARS-CoV-2 are asymptomatic spreaders. About 80% of those who are symptomatic, developing COVID-19, have mild disease displaying dry cough, fever, and fatigue. The resulting 20% of symptomatic patients accounts for those who develop progressive respiratory distress and sometimes multi-organ failure, among other complications. We’re learning more about anosmia, cardiac injury, and “COVID-toes.” What’s known about COVID-19 and SARS-CoV-2 continues to evolve. Dr. Raymund Razonable walks through a recently published update on the management of COVID-19. 

Time Stamps:
1:18 – New signs and symptoms of COVID-19.
3:30 – Testing characteristics (sensitivity, specificity, and indications)  of the molecular and serologic testing for SARS-CoV-2
6:22 – Risk factors and the prediction of disease progression for patients hospitalized with COVID-19
9:28 – Hyper-inflammatory syndrome and progression to multi-system organ failure syndrome
10:45 – Multisystem inflammatory syndrome in children (MIS-C)
11:22 – Cardiac complications – 3 factors
12:50 – Diagnosis and treatment of co-infection in hospitalized patients (COVID-19 and flu, COVID-19 and pneumonia)
16:31 – Evidence-based treatment based on the 3 phases of COVID-19 viremic phase, pneumonic phase, hyperinflammation phase
18:06 – Remdesivir update
21:00 – Hydroxychloroquine update
23:25 – Favipiravir and lopinavir-ritonavir update
23:53 – Treatment of the hyperinflammatory phase (sarilumab, tocilizumab, lenzilumab, anakinra,)
27:13 – Convalescent plasma
28:04 – Discharge and social determinants of health
33:40 – Telehealth and remote monitoring
35:40 – Health disparities and telehealth
37:47 – What’s the next development Infectious Disease specialists are looking for in relation to the COVID-19 pandemic?

See the article here:
A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting https://doi.org/10.1016/j.mayocp.2020.05.010

AskMayoExpert COVID-19 Resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Podcast Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp